Literature DB >> 9266967

Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for activity.

R Candau1, D M Scolnick, P Darpino, C Y Ying, T D Halazonetis, S L Berger.   

Abstract

The ability of p53 to function as a tumor suppressor is linked to its function as a transcriptional activator, since p53 mutants that do not transactivate are unable to suppress tumor cell growth. Previous studies identified an activation domain in the amino terminal 40 residues of the protein, a region that binds to several general transcription factors and to some oncogene products. For example, mdm-2, a cellular oncoprotein, binds to this region and represses p53 transactivation. Here we describe a new activation domain within the amino terminus of p53 that maps between amino acids 40-83, and whose residues trp-53 and phe-54 are critical for function both in yeast and in mammalian cells. In vivo studies in yeast show that the new activation subdomain, unlike the previously described, is mdm-2 independent. Both p53 activation subdomains (1-40 and 40-83) require the yeast adaptor complex ADA2/ADA3/GCN5 for transcriptional activation. Moreover, since activation by p53 requires GCN5's enzymatic histone acetyltransferase domain, p53 may regulate gene expression by influencing chromatin modification.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266967     DOI: 10.1038/sj.onc.1201244

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  68 in total

1.  Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2.

Authors:  Sridharan Rajagopalan; Antonina Andreeva; Trevor J Rutherford; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-26       Impact factor: 11.205

Review 2.  Posttranslational modification of p53: cooperative integrators of function.

Authors:  David W Meek; Carl W Anderson
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

3.  Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage.

Authors:  Connie Chao; Zhiqun Wu; Sharlyn J Mazur; Helena Borges; Matteo Rossi; Tongxiang Lin; Jean Y J Wang; Carl W Anderson; Ettore Appella; Yang Xu
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

4.  The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific.

Authors:  Jennifer M Smith; Lawton J Stubbert; Jeffrey D Hamill; Bruce C McKay
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

5.  Multivalent binding of p53 to the STAGA complex mediates coactivator recruitment after UV damage.

Authors:  Armin M Gamper; Robert G Roeder
Journal:  Mol Cell Biol       Date:  2008-02-04       Impact factor: 4.272

6.  Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2.

Authors:  Josephine C Ferreon; Chul Won Lee; Munehito Arai; Maria A Martinez-Yamout; H Jane Dyson; Peter E Wright
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-08       Impact factor: 11.205

7.  Extensive post-translational modification of active and inactivated forms of endogenous p53.

Authors:  Caroline J DeHart; Jasdave S Chahal; S J Flint; David H Perlman
Journal:  Mol Cell Proteomics       Date:  2013-09-20       Impact factor: 5.911

8.  The C terminus of p53 family proteins is a cell fate determinant.

Authors:  Kelly Lynn Harms; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

9.  Guilty as CHARGED: p53's expanding role in disease.

Authors:  Jeanine L Van Nostrand; Laura D Attardi
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  The expanding universe of p53 targets.

Authors:  Daniel Menendez; Alberto Inga; Michael A Resnick
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.